Description
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older with Cystic Fibrosis
| Status | Active |
|---|---|
| Effective start/end date | 3/21/19 → 1/1/21 |
Funding
- Vertex Pharmaceuticals Incorporated
Fingerprint
Double-Blind Method
Cystic Fibrosis
Safety
VX